| Mandeep S Bakshi, MD | |
|
401 Takoma Ave, Greeneville, TN 37743-4647 | |
| (423) 278-1743 | |
| (423) 278-1930 |
| Full Name | Mandeep S Bakshi |
|---|---|
| Gender | Male |
| Speciality | Sleep Medicine |
| Experience | 37 Years |
| Location | 401 Takoma Ave, Greeneville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669458857 | NPI | - | NPPES |
| 1522612 | Medicaid | TN | |
| 4330458 | Other | TN | BCBS OF TN |
| 891087Y | Medicaid | NC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indian Path Community Hospital | Kingsport, TN | Hospital |
| Greeneville Community Hospital | Greeneville, TN | Hospital |
| Hawkins County Memorial Hospital | Rogersville, TN | Hospital |
| Johnson City Medical Center | Johnson city, TN | Hospital |
| Entity Name | Summit Medical Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659090298 PECOS PAC ID: 2860396330 Enrollment ID: O20031125000793 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Scientists are reporting that the controversy surrounding whether selenium can fight cancer in humans might come down to which form of the essential micronutrient people take.
Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
The Associated Press: "His health care remake near collapse, President Barack Obama on Wednesday implored lawmakers not to abandon a historic opportunity even as he accepted part of the blame for failing to sell the complex plan to average Americans ... Obama defended his ambitious proposal, saying it would protect most Americans from being rejected for insurance if they get sick, preserve choice of doctors, bring down the federal deficit and provide affordable coverage for millions now uninsured" (Alonso-Zaldivar, 1/27).
› Verified 1 days ago
| Entity Name | Takoma Regional Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699819003 PECOS PAC ID: 8729189295 Enrollment ID: O20070727000394 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Scientists are reporting that the controversy surrounding whether selenium can fight cancer in humans might come down to which form of the essential micronutrient people take.
Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
The Associated Press: "His health care remake near collapse, President Barack Obama on Wednesday implored lawmakers not to abandon a historic opportunity even as he accepted part of the blame for failing to sell the complex plan to average Americans ... Obama defended his ambitious proposal, saying it would protect most Americans from being rejected for insurance if they get sick, preserve choice of doctors, bring down the federal deficit and provide affordable coverage for millions now uninsured" (Alonso-Zaldivar, 1/27).
› Verified 1 days ago
| Entity Name | Wellmont Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780986257 PECOS PAC ID: 8123291739 Enrollment ID: O20111026000909 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Scientists are reporting that the controversy surrounding whether selenium can fight cancer in humans might come down to which form of the essential micronutrient people take.
Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
The Associated Press: "His health care remake near collapse, President Barack Obama on Wednesday implored lawmakers not to abandon a historic opportunity even as he accepted part of the blame for failing to sell the complex plan to average Americans ... Obama defended his ambitious proposal, saying it would protect most Americans from being rejected for insurance if they get sick, preserve choice of doctors, bring down the federal deficit and provide affordable coverage for millions now uninsured" (Alonso-Zaldivar, 1/27).
› Verified 1 days ago
| Entity Name | App Of Tennessee Hm, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396160768 PECOS PAC ID: 5395960694 Enrollment ID: O20140630001088 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Scientists are reporting that the controversy surrounding whether selenium can fight cancer in humans might come down to which form of the essential micronutrient people take.
Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
The Associated Press: "His health care remake near collapse, President Barack Obama on Wednesday implored lawmakers not to abandon a historic opportunity even as he accepted part of the blame for failing to sell the complex plan to average Americans ... Obama defended his ambitious proposal, saying it would protect most Americans from being rejected for insurance if they get sick, preserve choice of doctors, bring down the federal deficit and provide affordable coverage for millions now uninsured" (Alonso-Zaldivar, 1/27).
› Verified 1 days ago
| Entity Name | East Tennessee Pulmonary And Sleep Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962035774 PECOS PAC ID: 6709298342 Enrollment ID: O20201223001851 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Scientists are reporting that the controversy surrounding whether selenium can fight cancer in humans might come down to which form of the essential micronutrient people take.
Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
The Associated Press: "His health care remake near collapse, President Barack Obama on Wednesday implored lawmakers not to abandon a historic opportunity even as he accepted part of the blame for failing to sell the complex plan to average Americans ... Obama defended his ambitious proposal, saying it would protect most Americans from being rejected for insurance if they get sick, preserve choice of doctors, bring down the federal deficit and provide affordable coverage for millions now uninsured" (Alonso-Zaldivar, 1/27).
› Verified 1 days ago
| Entity Name | Dr Mandeep Bakshi Pulmonary & Sleep Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730836016 PECOS PAC ID: 7113394446 Enrollment ID: O20221031000157 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Scientists are reporting that the controversy surrounding whether selenium can fight cancer in humans might come down to which form of the essential micronutrient people take.
Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
The Associated Press: "His health care remake near collapse, President Barack Obama on Wednesday implored lawmakers not to abandon a historic opportunity even as he accepted part of the blame for failing to sell the complex plan to average Americans ... Obama defended his ambitious proposal, saying it would protect most Americans from being rejected for insurance if they get sick, preserve choice of doctors, bring down the federal deficit and provide affordable coverage for millions now uninsured" (Alonso-Zaldivar, 1/27).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mandeep S Bakshi, MD 1404 Tusculum Blvd 2200, Greeneville, TN 37745-4395 Ph: (423) 798-8052 | Mandeep S Bakshi, MD 401 Takoma Ave, Greeneville, TN 37743-4647 Ph: (423) 278-1743 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Scientists are reporting that the controversy surrounding whether selenium can fight cancer in humans might come down to which form of the essential micronutrient people take.
Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
The Associated Press: "His health care remake near collapse, President Barack Obama on Wednesday implored lawmakers not to abandon a historic opportunity even as he accepted part of the blame for failing to sell the complex plan to average Americans ... Obama defended his ambitious proposal, saying it would protect most Americans from being rejected for insurance if they get sick, preserve choice of doctors, bring down the federal deficit and provide affordable coverage for millions now uninsured" (Alonso-Zaldivar, 1/27).
› Verified 1 days ago
Robert W. Locklear, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 895 E Andrew Johnson Hwy, Greeneville, TN 37745 Phone: 423-639-3330 Fax: 423-639-3342 | |
Maynard W Austin, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1404 Tusculum Blvd, Laughlin Mob, Suite 3100, Greeneville, TN 37745 Phone: 423-638-4114 | |
Muhammad M. Akmal, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 401 Takoma Ave, Greeneville, TN 37743 Phone: 423-278-1743 Fax: 423-278-1930 | |
Dr. Hiren B Patel, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1420 Tusculum Blvd, Greeneville, TN 37745 Phone: 423-783-6400 | |
Dr. Isioma Aninyei, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 401 Takoma Ave, Greeneville, TN 37743 Phone: 828-687-5616 Fax: 828-650-8076 | |
Kimi Hmar Zook, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 810 W Church St, Greeneville, TN 37745 Phone: 423-798-1749 Fax: 423-798-1755 | |
Thomas F Beckner Iii, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1404 Tusculum Blvd, Laughlin Mob, Suite 3100, Greeneville, TN 37745 Phone: 423-638-4114 |